Loading...
Please wait, while we are loading the content...
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
| Content Provider | Europe PMC |
|---|---|
| Author | Shrivastava, Trilok Van Rhee, Frits Al Hadidi, Samer |
| Copyright Year | 2023 |
| Abstract | AbstractRelapsed/refractory multiple myeloma remains a challenging disease necessitating the development of more effective treatment options. In the past decade, myeloma therapies have made significant advancements with the introduction of new treatment modalities. One of the new major targets for these novel therapeutics has been B-cell maturation antigen (BCMA), which is expressed on mature B-lymphocytes and plasma cells. There are three main categories of BCMA-targeted therapies currently available, including bispecific antibodies (BsAbs), antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies. In this review, we discuss the existing BCMA-targeted therapies and provide insights into currently available treatment and future developments, with a particular focus on clinical efficacy and common drug-related adverse events. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10290473&blobtype=pdf |
| Page Count | 24 |
| Journal | OncoTargets and Therapy [Onco Targets Ther] |
| Volume Number | 16 |
| PubMed Central reference number | PMC10290473 |
| PubMed reference number | 37359353 |
| e-ISSN | 11786930 |
| DOI | 10.2147/ott.s370880 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2023-06-20 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2023 Shrivastava et al. |
| Subject Keyword | BCMA multiple myeloma bispecific antibody BiTE CAR T cells B-cell maturation antigen |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |